Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 201–300 of 1,086
Enzan, N., Miyazawa, K., Koyama, S., Kurosawa, R., Ieki, H., Yoshida, H., Takechi, F., Fukuyama, M., Osako, R., Tomizuka, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64659-6 · Cited by 13
“10c – d and Supplementary Data 41 – 42).”
Ahmed, M., Burhan, M., Shafiq, A., Hashmi, T. M., Ahmed, R., Fudim, M., Mentz, R. J., & Fonarow, G. C. (2025) · Clinical Cardiology · doi:10.1002/clc.70234 · Cited by 12
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Dietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 14
Dardari, Z., Yao, Z., Zhang, J., Bakoyannis, G., Nan, H., Staten, L. K., Jha, K. K., Tasdighi, E., Jelwan, Y. A., Burka, S., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.075327 · Cited by 15
Gasoyan, H., Schulte, R. J., Boyer, C., Casacchia, N. J., Butsch, W. S., Le, P. N. B., Aminian, A., Griebeler, M. L., Burguera, B. G., & Rothberg, M. B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70660 · Cited by 13
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Mahmod, M., Bull, S., Kailayanathan, T., Davis, T. A., Borlotti, A., Popescu, I. A., Das, I., Wamil, M., Thomaides-Brears, H. B., Banerjee, R., et al. (2025) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-025-03455-1 · Cited by 10
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
“В исследовании SUMMIT препарат продемонстрировал выраженный эффект, снизив риск госпитализаций по поводу ХСН на 38% [36].”
The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review
Biondi, F., & Madonna, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082705 · Cited by 12
“HFpEF has been specifically addressed by four specific large randomized controlled trials that have shown improvements in quality of life [22,23], HF hospitalization [21], and major adverse cardiovascular events [39].”
Talavera, J. A., Teixeira, L., Klein, B., Lopes, R. R. D. S., Urina‐Jassir, D., Navalha, D. D. P., Bettinotti, B. G. M., Fernandez, N., Urina‐Triana, M., Welty, F. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70102 · Cited by 11
Salah, H. M., Ambrosy, A. P., Biegus, J., Bocchi, E. A., Butler, J., Chioncel, O. D., Cotter, G., Davison, B. A., Dzudié, A., Freund, Y., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.09.020 · Cited by 11
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
“%) compared with placebo [45, 46].”
InfluentialCurrent Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Obesity and Cardiometabolic Disease: Insights From Genetic Studies
Dash, S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.034 · Cited by 11
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
“Overall, the results over a median of 2 years of follow-up demonstrated a reduced risk of worsening heart failure symptoms and improved health status in patients with heart failure with pre-served ejection fraction, functional impairment, and obesity [55].”
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 23
Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., et al. (2026) · Sports Medicine · doi:10.1007/s40279-025-02386-0 · Cited by 9
“These three incretin-based medications also previously improved 6-min walking distance in patients with overweight or obesity and heart failure [45–47].”
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
“The SUMMIT trial also showed similar outcomes by reducing the risk of cardiovascular death, heart failure exacerbation and improving functional capacity of patients [69].”
Advanced chronic kidney disease coexisting with heart failure: navigating patients’ management
Zoccali, C., Levin, A., Mallamaci, F., Giugliano, R. P., & Caterina, R. D. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf128 · Cited by 12
“The selection of specific GLP-1 RAs with proven cardiovascular benefits ( e.g. semaglutide, tirzepatide) is recommended given the high risk of cardiovascular events in patients with CKD and HF [55 , 56 ].”
Obesity and inflammation in chronic and acute heart failure
Cotter, G., Petrie, M. C., Butler, J., Davison, B. A., Chioncel, O. D., Biegus, J., Pagnesi, M., Voors, A. A., Metra, M., Ponikowski, P. P., et al. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10518-x · Cited by 9
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112294 · Cited by 12
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Vilsbøll, T., Malecki, M. T., Sharma, P., Thieu, V. T., Chivukula, K. K., & Kiljanski, J. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16592 · Cited by 12
Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF
Doiron, J. E., Elbatreek, M. H., Xia, H., Yu, X., Gehred, N., Gromova, T., Chen, J., Driver, I. H., Muraoka, N., Jensen, M. B., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.011 · Cited by 12
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Ostrominski, J. W., Neuen, B. L., Claggett, B. L., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., Zannad, F. M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.028 · Cited by 9
Self-citationRole of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
“Beyond this local effect, chronic and low-grade systemic inflammation is also believed to play a central role in HFpEF, as observed in clinical trials showing elevated baseline elevated C-reactive protein levels in this population [64,75].”
Kobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 10
“113) Although current guidelines do not yet recommend GLP-1 RAs for the treatment of HF, this emerging evidence from these trials may influence forthcoming recommendations.”
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Khan, M. S., Dawood, M. H., Handelsman, Y., Anker, S. D., Coats, A. J. S., Green, J. B., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag201 · Cited by 9
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
Karthikeyan, G., Devasenapathy, N., Ghosh, A., Kini, P. R., Varyani, R., Satheesh, S., Gupta, M. D., Palleda, G. M., Sethi, R., Yadav, S., et al. (2026) · JAMA · doi:10.1001/jama.2026.7335 · Cited by 10
Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025
Wilk, M. M., & Tymków, R. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12120484 · Cited by 12
“Recent clinical trials and large-scale analyses evaluating GLP-1 receptor agonists, including semaglutide and tirzepatide, have demonstrated significant clinical benefits in patients with HFpEF, particularly in those with obesity [91–95].”
Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction
Packer, M., Ho, J. E., Petrie, M. C., Schiattarella, G. G., Butler, J., Lam, C. S. P., Vaduganathan, M., Zannad, F. M., & Borlaug, B. A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103046 · Cited by 10
Self-citationSevere obesity in human HFpEF alters contractile protein function and organization
Jani, V., Rhodehamel, M., Fenwick, A. J., Ma, W., Fisher, E., Giannakopoulos, M. T., Moon, S., Castillo, R. L., Kennedy, L., Irving, T. C., et al. (2026) · Science · doi:10.1126/science.adz7118 · Cited by 13
Kittipibul, V., Ambrosy, A. P., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10498-y · Cited by 10
“Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, lead to significant reductions in hsCRP levels in obesity-related HFpEF [17, 18].”
Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
Wang, W. T., Green, D. B., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Forst, B. J., Allam, M., Sarkis, P., Bcharah, G., Farina, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051108 · Cited by 9
“In addition, the SUMMIT trial utilized tirzepatide, a dual GIP and GLP1 receptor agonist, in patients with HFpEF [17].”
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
“51 The SURPASS-CVOT trial (NCT04255433) is currently under way to study cardiovascular outcomes of tirzepatide treatment compared with dulaglutide in patients with T2D.”
Mansoor, M. A. (2025) · Physiologia · doi:10.3390/physiologia5030034 · Cited by 9
“Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, such as tirzepatide, have already demonstrated superior efficacy for weight loss and glycemic control compared to GLP-1 RAs alone [59,60].”
Abdelhamid, M., Abdrabou, M. M., Faris, E., Elkaffas, S. M. H., Hosny, M., & Hassan, A. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.17 · Cited by 12
“8 This suggests that GLP-1RAs can be beneficial in stabilising high-risk HFpEF patients and reducing subsequent exacerbations.”
InfluentialSaraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF
Komić, L., Komic, J., Pavlović, N., Kumrić, M., Bukić, J., Tomić, I. J., & Božić, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020612 · Cited by 10
“The SUMMIT trial subsequently demonstrated that tirzepatide reduced the composite of cardiovascular death or worsening heart failure while producing substantial gains in health status and physical function [154].”
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Packer et al. showed significant improvements in symptoms and exercise capacity among patients with heart failure with preserved ejection fraction (HFpEF) and obesity [60].”
Pop, A. S. K., Dănilă, M. D., Giuchici, S., Buriman, D. G., Lolescu, B. M., Sturza, A., Muntean, D. M., & Lascu, A. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0384 · Cited by 11
Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension
Schinzari, F., Montenero, R., Cardillo, C., & Tesauro, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040790 · Cited by 9
Fu, W., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., Liu, L., & Li, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16581 · Cited by 8
Duhan, S., Kurpad, K. P., Keisham, B., Shtembari, J., Brener, A., Kanakadandi, U. B., Garg, A., Adoni, N. A., & Mehta, S. S. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133604 · Cited by 8
Saito, Y., Tateishi, K., Kato, K., Kitahara, H., & Kobayashi, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5950-25 · Cited by 8
“The dual agonist of GLP-1 and glucose-dependent in-sulinotropic polypeptide receptors (e.g. tirzepatide) may be another promising pharmacological therapy for patients with diabetes and obesity, and clinical evidence has been accumulating (55, 56).”
Hullon, D., Janiec, K., Florova, V., Trach, A., Volkova, Y., & Mnevets, R. O. (2025) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000344 · Cited by 8
“Similar reductions of 34.9 – 37.2% were observed in the SUMMIT and other trials with tirzepatide [13,34,35].”
InfluentialAhR in biological processes of adipocytes and lipid metabolism in obesity: Friend and foe
Li, X., Wang, S., Mao, X., Fang, M., Liu, X., Jiang, J., & Jin, W. L. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123996 · Cited by 9
Angelopoulos, N., Livadas, S., Androulakis, I., Petkova, V., Rizoulis, A. A., Boniakos, A., Paparodis, R. D., Tzoulis, P., Mentzelopoulou, V., Florakis, D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109181 · Cited by 11
Grilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 9
Hypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives
Zhou, N., Zhong, S.-Y., Gao, P., He, F.-F., & Zhang, C. (2026) · Biomedicines · doi:10.3390/biomedicines14030595 · Cited by 9
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes
Patti, A. M., Giglio, R. V., Ciaccio, M., Stoian, A. P., Salmen, T., Bica, I.-C., Rangraze, I. R., El‐Tanani, M., Rizzo, M., & Rizvi, A. A. (2025) · Medicina · doi:10.3390/medicina61040664 · Cited by 9
“These foods, rich in nutrients with inflammatory properties, have antioxidant properties and are rich in omega 3 fatty acids and vitamins, especially vitamins C and D.”
Real-world efficacy of tirzepatide in patients with heart failure without diabetes
Augusto, S. N., Kaelber, D. C., & Tang, W. H. W. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.102998 · Cited by 8
Heart failure with preserved ejection fraction therapeutics: in search of the pillars
Rafei, A. E., Harrington, J., Tavares, C. A. M., Guimarães, P. O., Ambrosy, A. P., Bonaca, M. P., Sauer, A. J., Vardeny, O., & Canonico, M. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10524-z · Cited by 8
Modulating the Secretome of Fat to Treat Heart Failure
Salyer, L. G., Wang, Y., Ma, X., Foryst‐Ludwig, A., Kintscher, U., Chennappan, S., Kontaridis, M. I., & McKinsey, T. A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325593 · Cited by 8
Correale, M., Salzano, A., Tricarico, L., Cittadini, A., Crisci, G., Dattilo, G., Inciardi, R. M., Fiori, E., Paolillo, S., Ruocco, G. M., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106457 · Cited by 9
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Prevent Frailty, Prevent Cardiovascular Disease
Ijaz, N., Nanna, M. G., & Damluji, A. A. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101701 · Cited by 9
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 11
Reitsma, T. H., Savarese, G., Kuźma, Ł., Deo, S. V., Pennells, L. A. M., Hageman, S. H. J., Holtrop, J., Benson, L., Conrad, N., Lund, L. H., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag182 · Cited by 8
“10,11 However, patients with HFpEF have highly heterogeneous clinical profiles with varying prognosis, and absolute benefit of treatment options may vary greatly between patients.”
Costa, T. A., Felix, N. S., Chagas, G. C. L., Terán, S., Boslough, M., Shelar, V., Lee, M. M. Y., Pandey, A., Abreu, M., McGuire, D. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16512 · Cited by 7
“9 This larger sample allows for a more robust assessment of clinical outcomes that individual trials were not powered to detect — for example, revealing a statistically significant reduction in all-cause mortality not seen in any single trial.”
InfluentialWeight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Revolution in Stroke Treatment Over 50 Years and Predicting Stroke Care in 2050
Broderick, J. P. (2025) · Stroke · doi:10.1161/strokeaha.125.052583 · Cited by 7
Wu, J., Tseng, K., Kao, C., Hung, K.-C., Yu, T., & Lin, Y. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf663 · Cited by 9
Sowa, H., Karasaki, K., Ishiwata, M., Cheng, X., Hashimoto, M., & Ueda, K. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1766197 · Cited by 8
“The dual GIP/GLP1R agonist tirzepatide further improves outcomes in obese patients with heart failure with preserved ejection fraction (HFpEF), accompanied by reductions in paracardial fat (Kramer et al., 2025; Packer et al., 2025).”
Abdul‐Hafez, H. A., Awashra, A., Bdir, S., Saife, S., Salah, Q., Barbarawi, M., Swaileh, T., Emara, A., Elgendy, M. S., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70152 · Cited by 9
“Given the inadequate data on long-term cardiovascular mortality, it is recommended that HF patients use the drug with caution [72].”
Thomas, J., Dagan, M., Wang, B. H., Gutman, S., & Kaye, D. M. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013279 · Cited by 10
From obesity to cardiovascular disease: pathological basis and clinical implications
Nardin, M., Mehran, R., Oliva, A., Kedhi, E., Galasso, G., Nardin, S., Savonitto, S., Condorelli, G., & Luca, G. D. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.04.041 · Cited by 7
Lam, C. S. P., Contreras, J., Darwesh, R., Freitas, A. F., Kristensen, S. L., Kuwahara, K., Ludman, A. J., Ma, C., Marx, N., Mathisen, J., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag155 · Cited by 7
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Costa, T. A., & Harrington, J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001214 · Cited by 7
Coronary Microvascular Dysfunction
Carli, M. F. D. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.01.002 · Cited by 8
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
“…(2.4 mg) vs placebo Semaglutide improved symptom burden and physical function in obese patients with and without T2DM with HFpEF SUMMIT (2024) [47] Once weekly subcut Tirzepatide (15 mg) vs placebo Tirzepatide led to lower rates of the composite outcome of death from cardiovascular events and…”
InfluentialPatel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 10
“Furthermore, most existing trials have predominantly involved white populations, which limits the generalizability of their findings [ 13, 55].”
InfluentialThe Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Suter, B., Rhodes, A. L., Bigeh, A., Frommeyer, T. C., & Mehta, L. S. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00761-0 · Cited by 8
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
Obesity and Heart Failure With Reduced Ejection Fraction
Khan, M. S., Javaid, S. S., Petrie, M. C., Zieroth, S. R., Anker, S. D., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5083 · Cited by 12
Park, D., Fuge, J., Kamp, J. C., Harrigfeld, B., Berliner, D., Hoeper, M. M., & Olsson, K. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247582 · Cited by 7
Brown, J. M., & Huck, D. M. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102299 · Cited by 6
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf779 · Cited by 6
“43 In contrast, weight loss by lifestyle interventions have shown less efficacy in reducing risk of cardiovascular events; however, the average weight reduction in these studies has been considerably smaller.”
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“Despite these early successes, the role of GLP-1RAs in the standalone HF management is less well defined In HFpEF, semaglutide and tirzepatide have demonstrated improvements in symptoms, functional capacity, and weight loss, particularly in patients with obesity-related phenotypes [19,20].”
InfluentialThe role of GLP-1 in the pathophysiology and treatment of sepsis: a narrative review
Dimić, N., Djuric, M. D., Vejapi, M., Nenadic, I. B., Bobos, M. M., Bojic, S. C., Savić, P., Milanović, M., & Stevanovic, P. D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1612034 · Cited by 8
“Clinical data support their ability to reduce risks of heart failure (30), atherosclerosis (31), and hypertension (32), highlighting their potential as systemic therapeutics.”
Neves, J. S., Lobato, C. B., Leite, A. R., Vale, C., Vasques‐Nóvoa, F., Saraiva, F. A., Leite-Moreira, A. F., Holst, J. J., & Ferreira, J. P. (2025) · Obesity Reviews · doi:10.1111/obr.70043 · Cited by 11
Borlaug, B. A., Chirinos, J. A., Lewis, G. D., Redfield, M. M., Bertoni, A. G., Cadeiras, M., Chiamvimonvat, N., Desai, A. S., Givertz, M. M., Kass, D. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102714 · Cited by 9
Self-citationPediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future
Das, B. B. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44109 · Cited by 6
Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
“At 52 weeks, the mean percent decrease in the hsCRP was 38.8% in the tirzepatide group and 5.9% in the placebo group ( p 0.001) [62].”
InfluentialHarada, T., Kagami, K., Ishii, H., & Obokata, M. (2026) · Journal of Cardiology · doi:10.1016/j.jjcc.2026.01.014 · Cited by 6
Heart failure evidence update 2026
Liori, S., Kapelios, C. J., Savarese, G., & Filippatos, G. S. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10609-3 · Cited by 10
“…established efficacy of non-steroidal mineralocorticoid receptor antagonists (MRAs) [ 1 ], and incretin-based therapies in selected patients with mildly reduced (HFmrEF) and preserved ejection fractions (HFpEF) [ 2 , 3], populations with limited guideline-directed medical options until recently.”
Oikonomou, E. K., Chan, K., Patel, P., Wahome, E., Dangas, K., Desai, R., Sobirov, I., Khera, R., Petersen, S. E., Pugliese, F., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5116 · Cited by 11
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6
Ge, J. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000112 · Cited by 7
Self-citationOdoardo, L. A. F. D., Zucchetti, O., Sciatti, E., D’Isa, S., D’Elia, E., & Senni, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf032 · Cited by 6
“13 Exploratory subgroup analyses showed that the effect of tirzepatide on the primary outcome was homogeneous (e.g. for BMI > 5 vs. < 35 kg/m 2 or for NT-proBNP > 200 vs. 200 pg/mL).”
Screening for Undiagnosed Heart Failure: A Viewpoint
Ferreira, J. P., & Zannad, F. M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.04.016 · Cited by 6
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.